PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1425001
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1425001
Disease Control And Prevention Vaccine Market size was valued at USD 51,210.3 Million in 2023, expanding at a CAGR of 10.5% from 2024 to 2032.
Immunization is widely recognized as a significant achievement in public health throughout the twentieth century. Vaccines have proven to be highly effective in preventing diseases, saving lives, and reducing healthcare costs. The widespread adoption of vaccination has successfully prevented disability and death in numerous children, leading governments worldwide to prioritize vaccination in their public health services. China, for instance, has effectively controlled infectious diseases through its national immunization program, which is based on vaccination. The Centers for Disease Control and Prevention (CDC) plays a crucial role in recommending and promoting vaccination programs to protect individuals and communities from vaccine-preventable diseases. The CDC provides vaccination guidelines, monitors vaccine safety, conducts research on vaccine effectiveness, and collaborates with other organizations to ensure a comprehensive approach to disease prevention.
Disease Control And Prevention Vaccine Market- Market Dynamics
Rising incidence of infectious diseases worldwide and the adoption of vaccines are anticipated to propel the expansion of the Disease Control and Prevention Vaccine market.
The global incidence of infectious diseases is on the rise, and the use of vaccines is expected to play a significant role in controlling and preventing their spread. Vaccines are crucial in safeguarding public health, and as awareness about their importance increases, there is a growing adoption of vaccination programs worldwide. Governments, healthcare organizations, and individuals are recognizing the value of vaccines in protecting communities from the burden of infectious diseases. Throughout history, infectious diseases have caused immense suffering, both in terms of illness and death. According to the Center for Disease Control and Prevention, there were 10.2 million visits to physician offices for infectious and parasitic diseases, and 3.8 million emergency department visits with these diseases as the primary diagnosis. Ongoing research and development in vaccine technology hold promising prospects for market growth. However, it is important to note that stringent regulatory processes may pose challenges to the expansion of the Disease Control and Prevention Vaccine market.
Disease Control And Prevention Vaccine Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.5% over the forecast period (2024-2032)
Based on product type segmentation, Live-attenuated Vaccines was predicted to show maximum market share in the year 2023
Based on Route of administration segmentation, Injectable was the leading type in 2023
Based on Indication segmentation, Infectious Disease was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Disease Control And Prevention Vaccine Market is segmented on the basis of Product Type, Route of administration, Indication, and Region.
The market is divided into four categories based on product type: Live-attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines and Toxoid Vaccines. Live-attenuated vaccines dominate a substantial portion of the market. Renowned for their remarkable effectiveness, these vaccines closely mimic natural infections, providing robust and long-lasting immunity.
The market is divided into two categories based on Route of administration: Oral and Injectable. The injectable segment commands a substantial portion of the market. Injectable vaccines are delivered through injections, typically either intramuscularly (IM) or subcutaneously (SC), to stimulate the immune system and initiate an immune response.
The market is divided into two categories based on Indication: Infectious Disease, Cancer and Other Indication. The Infectious Disease segment holds significant sway over the market. Many nations implement immunization programs to control the spread of infectious diseases. These programs often include routine childhood vaccinations and targeted vaccinations for specific populations.
Disease Control And Prevention Vaccine Market- Geographical Insights
Geographically, this market is spread across various regions including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The market growth is expected to be driven by North America in the forecast period, primarily due to the availability of highly advanced technologies and the increasing development of innovative vaccines. North America, especially the United States, is renowned for its advanced healthcare infrastructure and research capabilities. The region is home to numerous pharmaceutical and biotechnology companies that heavily invest in research and development, leading to the development of cutting-edge technologies for vaccine production. By the end of 2022, the United States is projected to spend USD 4.5 trillion on healthcare, making it the country with the highest overall healthcare expenditure globally. According to the latest data and reports on healthcare in the United States, the country's overall spending in 2021 is estimated to reach USD 4.3 trillion, accounting for 18.5% of its GDP. Europe holds the second-largest region for market growth during the forecast period, primarily due to the increasing disease burden.
The Disease Control and Prevention Vaccine market encompasses a wide range of vaccines developed by various organizations and companies to combat different diseases. Notable contributors to vaccine advancements include the World Health Organization (WHO), National Institutes of Health (NIH), and private entities. The recent emergence of infectious diseases on an unprecedented scale has presented new challenges for vaccine developers, regulators, health authorities, and political constituencies. The manufacturing and distribution of vaccines are complex processes that require both speed and careful consideration of clinical development, emergency use authorization, vaccine safety monitoring, and surveillance of virus variants. It is crucial to prioritize access to vaccines and vaccination efforts in low- and middle-income countries. While the vaccine industry is smaller compared to the pharmaceutical industry, it is steadily growing. Companies within the vaccine industry engage in research, development, manufacturing, sales, marketing, and distribution of vaccines, with their revenue primarily derived from vaccine product sales.
In October 2023, the FDA has approved PENBRAYA (meningococcal groups A, B, C, W, and Y vaccine), according to Pfizer Inc. This is the first and only pentavalent vaccine that protects against the most common serogroups that cause meningococcal disease in adolescents and young adults (10-25 years of age). In order to help protect against the five most common meningococcal serogroups that cause the majority of invasive meningococcal disease (IMD) worldwide, PENBRAYA combines the components from two meningococcal vaccines: Nimenrix® (meningococcal groups A, C, W-135, and Y conjugate vaccine) and Trumenba® (meningococcal group B vaccine).
GLOBAL DISEASE CONTROL AND PREVENTION VACCINE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Merck & Co. GlaxoSmithKline plc.
Sanofi, AstraZeneca PLC
Pfizer Inc.
Astellas Pharma Inc.
Sinovac Biotech Ltd.
Daiichi Sankyo
Serum Institute of India Pvt. Ltd.